fashion -WSS

fashion

author：comprehensive 2025-08-31 16:43:07 - browse：97611

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Children’s Hospital revives plan for pedestrian bridge

WSS

How to fix the rural physician shortage in the U.S.

FDA does about

Clinical trials giant ICON acquires HumanFirst

Kenai launches with $82 million for Parkinson’s stem cell therapy

NEJM study measures Covid brain fog, impact on IQ

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

entertainment

fashion

knowledge

Hollywood unions extend contract negotiations for actors

Pfizer highlights cancer drugs it thinks could reignite investor interest

As demand for Covid shots wanes, Moderna seeks its next success

Congress gives doctors Medicare pay bump

DIEP, the 'gold standard' of breast reconstruction, is under threat

Scientists unlock the key to scar

New air purifier tech could be key to improving indoor air quality

How to address the problem of discarded donor organs

The high cost of giving birth even with insurance

Kenai launches with $82 million for Parkinson’s stem cell therapy

leisure time

Pfizer is about to make a big push in cancer. Will investors listen?

Pfizer is about to make a big push in cancer. Will investors listen?

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

House looks to weaken Medicare negotiation

Cholera vaccine supplies dangerously low, outbreaks surging

Cholera vaccine supplies dangerously low, outbreaks surging

hotspot

hotspot

leisure time

hotspot